Skip to content

Microcirculation and Coagulopathy in Sepsis

Relationship Between Microcirculatory Alterations and Coagulopathy in Sepsis: Prospective Observational Study.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07404475
Acronym
[MicroCOAG]
Enrollment
30
Registered
2026-02-11
Start date
2023-06-01
Completion date
2025-06-30
Last updated
2026-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coagulopathy, Sepsis

Keywords

sepsis, microcirculation, tissue oxygenation, coagulopathy, glycocalyx

Brief summary

Sepsis-induced coagulopathy (SIC) and microvascular dysfunction are hallmark features of sepsis, yet their longitudinal relationship remains poorly understood. The aim of this study is to investigate the interplay between sublingual microcirculation, endothelial damage, peripheral tissue oxygenation and coagulation parameters in patients with sepsis.

Detailed description

Prospective observational study. Inclusion criteria: adult (\>18 years of age) patients with sepsis or septic shock. Exclusion criteria:sepsis for more than 24 hours, pre-existing coagulopathy (severe liver disease, inherited bleeding disorders), concurrent use of therapeutic anticoagulation or thrombolytic agents, factors impeding the sublingual microvascular assessment (including maxillo-facial trauma or recent oral surgery) pregnancy and inability to obtain informed consent. For all patients we will record age, gender, admission diagnosis, source of sepsis, comorbidities, the Sequential Organ Failure Assessment (SOFA), the Acute Physiology and Chronic Evaluation II (APACHE II) and the Simplified Acute Physiology Score II (SAPS II). Clinical and laboratory data will be collected daily from day 0 to day 4, including mean arterial pressure (MAP), heart rate (HR), arterial lactate levels, use of sedatives, vasoactive agents with dosage and anticoagulant angents. At day 0, arterial blood samples will be withdrawn and immediately centrifuged; plasma samples will be stored at -70°C for measurement of Syndecan-1 and thrombomodulin levels.Standard coagulation laboratory tests will be analysed daily from day 0 to day 4, including platelet count, international normalized ratio (INR), activated partial thromboplastin time (aPTT), fibrinogen, antithrombin and D-dimer levels. The sepsis-induced coagulopathy (SIC) and the disseminated intravascular coagulation (DIC) scores will be calculated daily. Thromboelastography will be performed daily. The sublingual microcirculation will be assessed on day 0 and day 4 to evaluate parameters of vessel density and microvascular flow quality. Near Infrared Spectroscopy will be used on day 0 to evaluate tissue (thenar eminence) O2 saturation and its dynamic changes during a vascular occlusion test, providing indices of tissue O2 extraction capacity and microvascular reactivity.Data from previous studies suggest that at least 50% of patients with sepsis present with coagulopathy. The hypothesis underlying this study is that patients who develop sepsis-induced coagulopathy exhibit more severe microcirculatory alterations at the time of sepsis diagnosis. In a previous study involving septic patients, we observed a baseline Perfused Vessel Density (PVD) of 22.8±4.7 mm/mm2. Based on these data, and assuming a mean difference in PVD of at least 20% (±5%) between patients who develop SIC and those who do not (unpaired samples t-test), it was calculated that a total sample size of 30 patients would be sufficient to demonstrate a statistically significant difference with a power of 80% and an alpha error of 0.05.

Interventions

None listed

Sponsors

Università Politecnica delle Marche
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* adult (\>18 years of age) * sepsis or septic shock

Exclusion criteria

* sepsis for more than 24 hours * pre-existing coagulopathy * concurrent use of therapeutic anticoagulation or thrombolytic agents * factors impeding the sublingual microvascular assessment * pregnancy * inability to obtain informed consent

Design outcomes

Primary

MeasureTime frameDescription
Perfused vessel densityday 0 (on enrollment)difference between patients with sepsis induced coagulopathy and patients without coagulopathy

Secondary

MeasureTime frameDescription
variations in microvascular parametersday 0 to day 4 (96 hours)evolution of microcirculatory alterations in patients with or without coagulopathy

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026